Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Endpoints News image

News from Endpoints News

See all of Endpoints News’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve aggregated 609 of Endpoints News’s headlines and news stories over the past 3 months.

Ground News rates Endpoints News’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to Endpoints News. You can read more about how we’ve determined Endpoints News’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.

Information about Endpoints News

Where is Endpoints News located?Endpoints News's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Endpoints News News

Korean startup Curogen seeks global expansion, new funding to back autoimmune drugs

Korean startup Curogen seeks global expansion, new funding to back autoimmune drugs

A South Korean biotech working on multi-specific autoimmune disease treatments is looking to make a leap into the US. Curogen, based in Seoul and backed by local investors, announced Monday that it plans to open ...See the Story

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Eli Lilly · Indianapolis

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

CHICAGO — Self-described “blunt pharma executives” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a conversation with the Indianapolis ...See the Story

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

100% Center coverage: 2 sources

(MedPage Today) -- CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09...See the Story

Kymera Reports Early-Stage Success for Drug Meant to Rival Sanofi and Regeneron’s Dupixent

100% Center coverage: 1 sources

A new study finds preliminary signs the therapy might tamp down a class of immune signals linked with chronic conditions.Cambridge, Massachusetts · Cambridge See the Story

Vera Drug Scores in Closely Watched Study in Rare Kidney Disease

100% Center coverage: 2 sources

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year.Innovation See the Story

ASCO 25: AZ Pitches Upfront Oral SERD Use in Breast Cancer

100% Center coverage: 1 sources

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line dataBreast Cancer See the Story

In race with Merus, Bicara makes the case for two-year survival data

CHICAGO — Forced to play defense after its stock price fell 40% last month on competing data, Bicara hopes to win back some favor with new results for its head and neck cancer drug. In the ...Chicago, IL · Chicago See the Story

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

CHICAGO — Checkpoint therapies, which made their name as treatments for patients with metastatic cancer, are now being implemented in a wide range of less-advanced cancers alongside surgery. The goal is not just to extend a ...Cancer · Chicago Read Article

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

CHICAGO — Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease drug was put on a clinical hold because of safety issues in animal studies. ...Chicago, IL · Chicago Read Article

New three-drug combination could help women with aggressive breast cancer live longer, study suggests

57% Center coverage: 7 sources

NHS · United Kingdom See the Story

FDA approves Moderna’s new lower-dose COVID-19 vaccine

59% Center coverage: 129 sources

FDA · United States See the Story

Breaking News Topics Related to Endpoints News